TREATMENT OF STAGE I DIFFUSE AGGRESSIVE LYMPHOMAS

I期弥漫性甲状腺肿患者的剖腹手术期放射治疗 侵袭性淋巴瘤是中等成功的。 本研究设计 以提高放射治疗的功效并消除 需要分期剖腹手术 在本研究中，临床I期和IE期 患者用四个周期的ProMACE-MOPP化疗（在 大约75%的骨髓抑制药物的剂量最初 在ProMACE和MOPP中使用），随后进行累及野放射至40戈伊。 有56例可评价患者入组研究，其中54例（96%） 完全缓解了。 有一个复发。 三 患者死亡：两名从未达到完全缓解的患者和一名 一名四年多来一直处于完全反应状态的妇女在 她的第二次冠状动脉搭桥手术 待遇不错 耐受性好，没有严重的长期毒性， 中位随访时间为4年。 很难再改进 这些结果或降低毒性。

Radiation therapy in laparotomy-staged patients with Stage I diffuse aggressive lymphomas is moderately successful. This study was designed to improve upon the efficacy of radiation therapy and to eliminate the need for staging laparotomy. In this study, clinical Stage I and IE patients are treated with four cycles of ProMACE-MOPP chemotherapy (at approximately 75% of the dosages of myelosuppressive drugs originally used in ProMACE and MOPP) followed by involved field radiation to 40 Gy. There are 56 evaluable patients entered on study of whom 54 (96%) achieved a complete remission. There has been one relapse. Three patients died: the two who never achieved a complete response, and one woman who had been in complete response for over four years died during her second coronary artery bypass surgery. The treatment is well tolerated and there have been no serious long-term toxicities with a median follow-up of four years. It would be difficult to improve upon these results or to decrease the toxicities.